Tonix Pharmaceuticals Q3 EPS $(1.83) Misses $(1.49) Estimate, Sales $3.99M Miss $5.80M Estimate
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals reported Q3 losses of $(1.83) per share, missing the analyst consensus estimate of $(1.49) by 22.82 percent. This is a 57.54 percent increase over losses from the same period last year. The company also reported quarterly sales of $3.99 million, missing the analyst consensus estimate of $5.80 million by 31.22 percent.
November 09, 2023 | 11:33 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Tonix Pharmaceuticals reported larger than expected losses and lower than expected sales for Q3.
Tonix Pharmaceuticals reported larger than expected losses and lower than expected sales for Q3. This negative financial performance is likely to negatively impact the company's stock price in the short term.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100